Andrew Sloan, MD, & Ian Lee MD
There are currently 5 Studies of LITT for Adults with Brain Tumors with primary and recurrent gliomas as well as brain metastasis as indicated in the Table below. Below, we highlight 2 of them (for Brain metastasis and recurrent glioma) in more detail.
| TITLE | CONDITION | TREATMENT | LOCATION |
| LITT + Hypofractionated RT for newly diagnosed Glioma | Newly diagnosed Glioma | LITT + Hypofractionated RT | University of MD Proton Center,;UCH Kaufman Cancer Center |
| Expedited LITT + Chemradiation for newly diagnosed HGG | Newly diagnosed Glioma | LITT + Hypofractionated RT + TMZ | Case Comprehensive Cancer Center |
| LITT + Hypofractionalted RT for Recurrent Glioma | Recurrent Glioma | LITT + Hypofractionated RT | University of Maryland, UCH Kaufman Cancer Center, Baltimore Washington Medical Center |
| LITT combined with Checkpoint Inhibitor for recurrent GBM | Recurrent GBM | LITT + Neoadjuvant Pembrolizumab | Universisty Hospitals-Seidman Cancer Center; Case Comprehensive Cancer Center |
| LITT + Pembrolizumab in Recurrent Brain Metastasis | Recurrent Brain Metastasis | LITT + Pembrolizumab | University of Florida, Jacksonville; McKnight Brain Institute, UF |
- LITT and Pembrolizumab in Recurrent Brain Metastasis
Brief Summary:
This is an open-label, historically controlled pilot study investigating the immune effect of Laser Interstitial ThermotHerapy (LITT)+ pembrolizumab in adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis after prior stereotactic radiosurgery (SRS).
Adult patients with a primary cancer approved by the FDA for treatment with an immune-checkpoint inhibitor who have recurrent brain metastasis that have failed stereotactic radiosurgery treatment will be screened. They will sign consent and complete screening procedures. Each patient will be scheduled to undergo biopsy and LITT treatment. Within two weeks of surgery, patients will begin receiving pembrolizumab every three weeks. Pembrolizumab infusions will continue until brain met recurrence per RANO for Brain Mets or up to two years, whichever comes first. Blood samples will be collected for immune monitoring. Tumor tissue will be collected for immune and genomic studies. Approximately 21 patients will be enrolled to accrue 15 evaluable subjects. Patients will be followed for survival data for one year or until death, whichever comes first.
Location: University of Florida, Gainesville, FL
2. Laser Interstitial Thermotherapy (LITT) Combined With Checkpoint Inhibitor for Recurrent GBM (rGBM)
Brief Summary:
The purpose of this study is to test the side effects and efficacy of using Laser Interstitial Thermotherapy (LITT) combined with Pembrolizumab. LITT is a minimally invasive surgical technique that uses a laser to heat brain tumors.
Pembrolizumab is an investigational (experimental) drug that works by helping participants’ immune system work correctly to detect and fight cancer cells. Pembrolizumab is experimental because it is not approved by the Food and Drug Administration (FDA), for this use, though it is approved to treat other cancers.
Location: University Hospitals-Seidman Cancer Center & Case Comprehensive Cancer Center, Cleveland, OH